dc.contributor.author |
Uysal, Ayse |
|
dc.contributor.author |
Akad Soyer, Nur |
|
dc.contributor.author |
Ozkan, Melda |
|
dc.contributor.author |
Sahin, Fahri |
|
dc.contributor.author |
Vural, Filiz |
|
dc.contributor.author |
Tobu, Mahmut |
|
dc.contributor.author |
Tombuloglu, Murat |
|
dc.contributor.author |
Saydam, Guray |
|
dc.date.accessioned |
2019-07-08T07:31:59Z |
|
dc.date.available |
2019-07-08T07:31:59Z |
|
dc.date.issued |
2018 |
|
dc.identifier.citation |
Uysal, A. Akad Soyer, N. Ozkan, M. Sahin, F . Vural, F. Tobu, M. Tombuloglu, M. Saydam, G. (2018). Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. Cilt:48. Sayı:1. 80-83 ss. |
tr_TR |
dc.identifier.uri |
http://hdl.handle.net/11616/12381 |
|
dc.description.abstract |
Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone.
Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. The patients were followed until March 2016 after CFZ treatment.
Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47-76) years. The median number of prior treatment lines was 3 (2-7). The median number of administered cycles of treatment for CFZ was 4 (1-10). The median overall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7-9) and 3 (2-16) months, respectively. The median overall survival was 8 (0.5-33) months.
Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients. |
tr_TR |
dc.language.iso |
eng |
tr_TR |
dc.publisher |
Tubıtak scıentıfıc & technıcal research councıl turkey, ataturk bulvarı no 221, kavaklıdere, ankara, 00000, turkey |
tr_TR |
dc.relation.isversionof |
10.3906/sag-1611-97 |
tr_TR |
dc.rights |
info:eu-repo/semantics/openAccess |
tr_TR |
dc.subject |
Agent carfılzomıb |
tr_TR |
dc.subject |
workıng group |
tr_TR |
dc.subject |
bortezomıb |
tr_TR |
dc.subject |
therapy |
tr_TR |
dc.subject |
multıcenter |
tr_TR |
dc.title |
Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience |
tr_TR |
dc.type |
article |
tr_TR |
dc.relation.journal |
Turkısh journal of medıcal scıences |
tr_TR |
dc.contributor.department |
İnönü Üniversitesi |
tr_TR |
dc.identifier.volume |
48 |
tr_TR |
dc.identifier.issue |
1 |
tr_TR |
dc.identifier.startpage |
80 |
tr_TR |
dc.identifier.endpage |
83 |
tr_TR |